Updated HARMONi Data Shows OS Benefit for Lung Cancer Therapy
Summit Therapeutics announced updated overall survival results at WCLC 2026 for ivonescimab plus chemotherapy in EGFR-mutated NSCLC, maintaining efficacy and safety profiles across regions.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day